Payment overview · 2025
General Payments
$3,762.77
42 reported records · 9 companies
Healthcare provider profile · identity verified
Melanie Mccarty, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · OWENSBORO, KY · NPI 1225519432
Verified facts
What the public records show
CMS Open Payments records show Melanie Mccarty, APRN received $3,762.77 in general payments during 2025 across 42 reported records.
Gilead Sciences, Inc. accounted for 87.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Epclusa.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Epclusa as an associated drug or biological on 4711 records involving 2021 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Epclusa by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $3,293.08 | 87.5% | 14 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $233.52 | 6.2% | 18 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $75.68 | 2.0% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $48.19 | 1.3% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $27.74 | 0.7% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.67 | 0.7% | 1 | 2025 |
| OWP Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.54 | 0.6% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $19.43 | 0.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.92 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $1,840.00 | 1 |
| Travel and Lodging | $1,236.30 | 3 |
| Food and Beverage | $686.47 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Epclusa Normalized: epclusa |
Drug | Gilead Sciences, Inc. | $3,222.30 | 8 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $125.39 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $108.13 | 9 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $48.19 | 2 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $48.19 | 2 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $43.42 | 2 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $32.26 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $27.74 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $27.74 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $24.67 | 1 | 2025 |
Source payment records
|
|||||
| Subvenite Normalized: subvenite |
Drug | OWP Pharmaceuticals, Inc. | $22.54 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Epclusa epclusa |
2025 | Epclusa | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Epclusa open payments reported associated product |
CMS Open Payments — General Payments 4711 supporting records · 2021 recipient NPIs · example record 1234350832 |
Epclusa · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 83 | 13 |
| Atorvastatin Calcium | Atorvastatin Calcium | 78 | 20 |
| Lisinopril | Lisinopril | 55 | 13 |
| Mounjaro | Tirzepatide | 46 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 39 | suppressed |
| Jardiance | Empagliflozin | 36 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 33 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 29 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 28 | suppressed |
| Carvedilol | Carvedilol | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Metformin Hcl | Metformin Hcl | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Ozempic | Semaglutide | 25 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Omeprazole | Omeprazole | 23 | suppressed |
| Potassium Chloride | Potassium Chloride | 23 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 19 | suppressed |
| Furosemide | Furosemide | 18 | suppressed |
| Losartan Potassium | Losartan Potassium | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 15 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Eliquis | Apixaban | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 12 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 11 | suppressed |
| Epclusa | Sofosbuvir/Velpatasvir | 11 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,762.77 · 42 records | Gilead Sciences, Inc. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, Auvelity, Epclusa, FANAPT, HETLIOZ, LYBALVI, MAVYRET, REZDIFFRA, Subvenite, VIVITROL, VRAYLAR, Wegovy | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Epclusa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Gilead Sciences, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error